Market News & Trends
Achaogen Announces FDA Acceptance of New Drug Application With Priority Review
Achaogen, Inc. recently announced the US FDA has accepted for review the company’s New Drug Application (NDA) for plazomicin for the treatment of complicated urinary…
Secondary Packaging – How “One-Stop-Shop” Solutions Can Help Address a Changing World
By: Daniela Geiger, Vetter, Product & Service Manager In a rapidly aging world, it could be difficult for today’s pharmaceutical and biotechnology companies to…
Platform Technology Company Cell Design Labs to be Acquired by Gilead
Cell Design Labs, Inc. recently announced that Gilead Sciences has agreed to acquire them in a structured buy out valued for up to $567 million,…
RespireRx Pharmaceuticals Announces Publication of Phase 2B PACE Study
RespireRx Pharmaceuticals Inc. recently announced that the results of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) clinical trial have been published by the principal…
Do's & Don'ts for Orphan Drug Support Programs
Getting personal with rare disease patients. By: Nancy Pilcher, RN, Director, Business Development, AmerisourceBergen Complex. It’s the word most often associated with the…
AMRI Doubles Bulk API Aseptic Manufacturing Capacity
AMRI, a global contract research, development, and manufacturing organization, has more than doubled its current bulk Active Pharmaceutical Ingredient (API) aseptic manufacturing capacity. The addition…
MonoSol Rx Changes Name, Expands CNS Portfolio
MonoSol Rx recently announced the change of its corporate name to Aquestive Therapeutics. The new name reflects the company's expanded capabilities in developing and commercializing…
Carrick Therapeutics Announces First Patient Dosed in Phase I Clinical Trial
Carrick Therapeutics recently announced that the first patient has been dosed in the Phase 1 clinical program of CT7001 - an orally bioavailable Cyclin-dependent Kinase…
LAM Therapeutics Announces Progress of its Clinical Portfolio With FDA Clearance
LAM Therapeutics, a 4Catalyzer company, advanced its clinical portfolio with the US FDA clearance of LAM’s Investigational New Drug (IND) application for LAM-003 in leukemia patients.…
NRGene & Tel Aviv Sourasky Medical Center Collaborate on Parkinson’s Genomes
NRGene, the worldwide leader in genomic assembly and analysis, has partnered with the Genetic Institute of Tel Aviv Sourasky Medical Center (TASMC) to perform genomic…
Inovio’s Cancer Immunotherapy Combined With Checkpoint Inhibitor Synergistically Shrinks Tumor & Improves Survival
Inovio Pharmaceuticals, Inc. demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in preclinical tumor…
Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial
Sevion Therapeutics, Inc. and Eloxx Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel translational read-through inducing drugs (TRIDs) for genetic diseases caused by nonsense mutations,…
PhaseBio Enters Worldwide License Agreement With MedImmune
PhaseBio Pharmaceuticals, Inc. recently announced it has entered an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for…
TGR-1202 Selected as the PI3K Delta Inhibitor to be Used in Multiple-Arm Comparison Study
TG Therapeutics recently announced that along with SWOG, the global cancer clinical trials group funded by the National Cancer Institute (NCI), it has initiated a…
CytomX Therapeutics Announces FDA Acceptance of IND. Triggers Milestone
CytomX Therapeutics, Inc. recently announced that Bristol-Myers Squibb has received acceptance of the Investigational New Drug application (IND) from the US FDA for a CTLA-4-directed…
Vaccinex & Catalent Biologics to Collaborate on Antibody-Drug Conjugate Development
Catalent Pharma Solutions and Vaccinex, Inc. recently announced an agreement to develop an antibody-drug conjugate (ADC) using Catalent’s proprietary SMARTag® conjugation platform and GPEx® cell…
Navitas Brings End-to-End R&D Solutions to the Generic Drug Industry
Navitas Life Sciences, a TAKE Solutions Enterprise, provides services and technology to deliver "first-to-file" results to generic drug companies around the globe, allowing them to…
G1 Therapeutics & AstraZeneca Enter Clinical Trial Collaboration
G1 Therapeutics, Inc. recently announced a clinical trial collaboration with AstraZeneca to evaluate AstraZeneca’s epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib)…
Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study
Aptevo Therapeutics Inc. recently announced recent developments related to the Company’s novel ADAPTIR bispecific antibody platform, including the planned commencement of a Phase 2 clinical…
Cesca Therapeutics Announces Issuance of Second Cellular Processing Patent Surrounding Company’s X-BACS Technology
Cesca Therapeutics Inc. recently announced that on November 21, 2017, the USPTO awarded the company a new US Patent No. 9,821,111 (the ‘111 patent), entitled…
